Citations

Clear

3138 citation(s) found for "Smith, AM".

NKAP Regulates Invariant NKT Cell Proliferation and Differentiation into ROR-γt–Expressing NKT17 Cells
Thapa, Puspa , Chen, Meibo W., McWilliams, Douglas C., Belmonte, Paul , Constans, Megan, Sant’Angelo, Derek B. , Shapiro, Virginia Smith , Belmonte, Paul J

Mayo Clinic

The Journal of Immunology | May 10, 2016 | Volume: 196 | Issue: 12 | Pages: 4987-4998

10.4049/jimmunol.1501653 | PMID 27183586 Get It

Abstract Invariant NKT (iNKT) cells are a unique lineage with characteristics of both adaptive and innate lymphocytes, and they recognize glycolipids presented by an MHC class I–like CD1d molecule. During thymic development, iNKT cells also differentiate into NKT1, NKT2, and NKT17 functional subsets that preferentially produce cytokines IFN-γ, IL-4, and IL-17, respectively, upon activation. Newly selected iNKT cells undergo a burst of proliferation, which is defective in mice with a specific deletion of NKAP in the iNKT cell lineage, leading to severe reductions in thymic and peripheral iNKT cell numbers. The decreased cell number is not due to defective homeostasis or increased apoptosis, and it is not rescued by Bcl-xL overexpression. NKAP is also required for differentiation into NKT17 cells, but NKT1 and NKT2 cell development and function are unaffected. This failure in NKT17 development is rescued by transgenic expression of promyelocytic leukemia zinc finger; however, the promyelocytic leukemia zinc finger transgene does not restore iNKT cell numbers or the block in positive selection into the iNKT cell lineage in CD4-cre NKAP conditional knockout mice. Therefore, NKAP regulates multiple steps in iNKT cell development and differentiation.
Implementation of a Regional Telephone Cardiopulmonary Resuscitation Program and Outcomes After Out-of-Hospital Cardiac Arrest
Bobrow, Bentley J., Vadeboncoeur, Tyler F. , Hu, Chengcheng , Mullins, Terry, Tormala, Wayne, Dameff, Christian , Gallagher, John V., Smith, Gary A. , Panczyk, Micah , Spaite, Daniel W.

Mayo Clinic

JAMA Cardiology | May 4, 2016 | Volume: 1 | Issue: 3 | Pages: 294

10.1001/jamacardio.2016.0251 | PMID 27438108 Get It

Effect of NBCe1 deletion on renal citrate and 2-oxoglutarate handling
Osis, Gunars , Handlogten, Mary E., Lee, Hyun‐Wook , Hering-Smith, Kathleen S. , Romero, Michael F. , Verlander, Jill W. , Weiner, I. David , Huang, Weitao, Weiner, I David , Romero, Michael F

Mayo Clinic

Physiological Reports | April 27, 2016 | Volume: 4 | Issue: 8 | Pages: e12778

10.14814/phy2.12778 | PMID 27117802 Get It

Representation of Women With Industry Ties in Ophthalmology
Reddy, Ashvini K. , Bounds, Gregory , Bakri, Sophie J. , Smith, Justine R. , Haller, Julia A. , Thorne, Jennifer E. , Gordon, Lynn K. , Smith, Justine

Mayo Clinic

JAMA Ophthalmology | April 21, 2016 | Volume: 134 | Issue: 6 | Pages: 636

10.1001/jamaophthalmol.2016.0552 | PMID 27101532 Get It

Assessment of physical function and participation in chronic pain clinical trials: IMMPACT/OMERACT recommendations
Taylor, Ann , Phillips, Kristine, Patel, Kushang V. , Turk, Dennis C., Dworkin, Robert H. , Beaton, Dorcas , Clauw, Daniel J. , Gignac, Monique A. M. , Markman, John D. , Williams, David A. , Bujanover, Shay, Burke, Laurie B. , Carr, Daniel B., Conaghan, Philip G. , Cowan, Penney, Farrar, John T. , Gewandter, Jennifer S. , Gilron, Ian , Goli, Veeraindar, Gover, Tony D., Haddox, J. David , Kopecky, Ernest A. , Malamut, Richard, Rappaport, Bob A., Simon, Lee S. , Singh, Jasvinder A. , Smith, Shannon M. , Tugwell, Peter , Vanhove, Gertrude F., Veasley, Christin , Walco, Gary A. , Wasan, Ajay D. , Witter, James, Choy, Ernest , Freeman, Roy L. , Kerns, Robert D. , Lee, David A. , Mease, Philip J. , Strand, Vibeke , Vanhove, Geertrui F. , Singh, Jasvinder A , Williams, David A , Wasan, Ajay D , Conaghan, Philip

Mayo Clinic

Pain | April 19, 2016 | Volume: 157 | Issue: 9 | Pages: 1836-1850

10.1097/j.pain.0000000000000577 | PMID 27058676 Get It

AbstractAlthough pain reduction is commonly the primary outcome in chronic pain clinical trials, physical functioning is also important. A challenge in designing chronic pain trials to determine efficacy and effectiveness of therapies is obtaining appropriate information about the impact of an intervention on physical function. The Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) and Outcome Measures in Rheumatology (OMERACT) convened a meeting to consider assessment of physical functioning and participation in research on chronic pain. The primary purpose of this article is to synthesize evidence on the scope of physical functioning to inform work on refining physical function outcome measurement. We address issues in assessing this broad construct and provide examples of frequently used measures of relevant concepts. Investigators can assess physical functioning using patient-reported outcome (PRO), performance-based, and objective measures of activity. This article aims to provide support for the use of these measures, covering broad aspects of functioning, including work participation, social participation, and caregiver burden, which researchers should consider when designing chronic pain clinical trials. Investigators should consider the inclusion of both PROs and performance-based measures as they provide different but also important complementary information. The development and use of reliable and valid PROs and performance-based measures of physical functioning may expedite development of treatments, and standardization of these measures has the potential to facilitate comparison across studies. We provide recommendations regarding important domains to stimulate research to develop tools that are more robust, address consistency and standardization, and engage patients early in tool development.
Human and Mouse Eosinophils Have Antiviral Activity against Parainfluenza Virus
Drake, Matthew G. , Bivins-Smith, Elizabeth R., Proskocil, Becky J. , Scott, Gregory D. , Lee, James J. , Lee, Nancy A., Fryer, A.D. , Nie, Zhenying , Jacoby, David B. , Fryer, Allison D , Drake, Matthew G

Mayo Clinic

American Journal of Respiratory Cell and Molecular Biology | April 6, 2016 | Volume: 55 | Issue: 3 | Pages: 387-394

10.1165/rcmb.2015-0405oc | PMID 27049514 Get It

Abstract Respiratory viruses cause asthma exacerbations. Because eosinophils are the prominent leukocytes in the airways of 60–70% of patients with asthma, we evaluated the effects of eosinophils on a common respiratory virus, parainfluenza 1, in the lung. Eosinophils recruited to the airways of wild-type mice after ovalbumin sensitization and challenge significantly decreased parainfluenza virus RNA in the lungs 4 days after infection compared with nonsensitized animals. This antiviral effect was also seen in IL-5 transgenic mice with an abundance of airway eosinophils (NJ.1726) but was lost in transgenic eosinophil-deficient mice (PHIL) and in IL-5 transgenic mice crossed with eosinophil-deficient mice (NJ.1726-PHIL). Loss of the eosinophil granule protein eosinophil peroxidase, using eosinophil peroxidase–deficient transgenic mice, did not reduce eosinophils’ antiviral effect. Eosinophil antiviral mechanisms were also explored in vitro. Isolated human eosinophils significantly reduced parainfluenza virus titers. This effect did not involve degradation of viral RNA by eosinophil granule RNases. However, eosinophils treated with a nitric oxide synthase inhibitor lost their antiviral activity, suggesting eosinophils attenuate viral infectivity through production of nitric oxide. Consequently, eosinophil nitric oxide production was measured with an intracellular fluorescent probe. Eosinophils produced nitric oxide in response to virus and to a synthetic agonist of the virus-sensing innate immune receptor, Toll-like receptor (TLR) 7. IFNγ increased expression of eosinophil TLR7 and potentiated TLR7-induced nitric oxide production. These results suggest that eosinophils promote viral clearance in the lung and contribute to innate immune responses against respiratory virus infections in humans.
Vertebral Artery Injury in Cervical Spine Surgery: Results from AOSpine North America Multicenter Study on 16,582 Patients
Kannan, Abhishek , Mai, Harry, Hsu, Wellington K. , Hilibrand, Alan S. , Traynelis, Vincent C. , Gokaslan, Ziya L. , Mroz, Thomas E. , Bydon, Mohamad , Smith, Zachary A. , Massicotte, Eric M. , Mai, Harry, Nassr, Ahmad , Arnold, Paul M. , Fehlings, Michael G. , Riew, Kiehyun Daniel

Mayo Clinic

Global Spine Journal | April 4, 2016 | Volume: 6 | Issue: 1_suppl | Pages: s-0036-1582986-s-0036-1582986

10.1055/s-0036-1582986 Get It

Introduction Vertebral artery injury is a rare but serious complication of cervical spine surgery with an overall incidence rate of 1.4% (Rampersaud, 2006). Iatrogenic injury of the vertebral artery can lead to serious complications including lateral medullary (Wallenberg) syndrome, quadriparesis, and mortality. The high rate of vertebral artery anomalies in the general population mandates assessment via advanced imaging modalities in the preoperative period (Schroeder, 2013). The rarity of this complication makes it difficult to set expectations after an injury is encountered. This study utilized a multi-center database to compile outcomes data after vertebral artery injury during a cervical spine procedure. Materials and Methods A multi-center retrospective case series was compiled involving 23 medical institutions. Inclusion criteria included patients who underwent cervical spine surgery between 2005–2011 and who sustained a vertebral artery injury. IRBs were obtained from all institutions and data was sent to a private research organization that collected and collated all of the data. Patients were evaluated on the basis of condition-specific functional status using the Neck Disability Index (NDI), modified Japanese Orthopaedic Association (mJOA) score, the Nurick scale, and the 36-Item Short-Form Health Survey (SF-36). Results Vertebral artery injuries were identified in a total of 14 of 16,582 total patients screened (8.4 per 10,000). The mean age of patients with vertebral artery injury was 59 years (+/− 10) with a female predominance (78.6%). Diagnoses of affected patients included 7 with myelopathy, 3 with radiculopathy, 1 with cervical instability, and 2 with metastatic disease. The mean duration of operative time for cases was 4.7 hours (+/− 1.8). Vertebral artery injury was also associated with substantial blood loss (770 mL), although only 3 cases required transfusion. Of the 14 cases, 7 occurred with an anterior only approach, 3 cases with posterior only approach, and 4 during circumferential approach. Average length of hospital stay for these patients was 10 days (+/− 8). Notably, 13 of the 14 (92.86%) cases reportedly resolved without residual deficits. Compared with preoperative baseline NDI, Nurick, and SF-36 physical and mental component scores for these patients, there were no observed changes after surgery ( p = 0.20 Ð 0.94). Conclusion Vertebral artery injuries are potentially catastrophic complications that can be sustained from either anterior or posterior cervical spine approaches. This adverse event is associated with an increase in hospital stay and functional disability measured on NDI score. However, the data from this study suggests that with proper steps to ensure hemostasis, patients recover function at a high rate and do not exhibit residual deficits (13 out of 14). Preoperative imaging studies may provide insight into VA anomalies and anatomic variations and are vital to the preoperative assessment. Furthermore, although surgeons should expect increased blood loss once a vertebral artery injury is encountered, patients do not often require a blood transfusion.
Blood lipids and prostate cancer: a Mendelian randomization analysis
Bonilla, Carolina , Holly, Jeff M.P. , Perks, Claire M. , Davies, Neil M , Haycock, Philip , Richards, J. Brent , Eeles, Rosalind A. , Easton, Doug , Olama, Ali Amin Al , Benlloch, Sara, MacInnis, Robert J. , Grönberg, Henrik , Haiman, Christopher A. , Schleutker, Johanna , Nordestgaard, Børge G. , Travis, Ruth C. , Neal, David E. , Pashayan, Nora , Stanford, Janet L. , Blot, William J. , Thibodeau, Stephen N. , Maier, Christiane, Kibel, Adam S. , Brenner, Hermann , Park, Jong, Kaneva, Radka , Batra, Jyotsna , Teixeira, Manuel R. , Micheal, Agnieszka, Pandha, Hardev , Smith, George Davey , Lewis, Sarah J. , Martin, Richard M. , Thibodeau, Stephen, Bull, Caroline J. , Yu, Oriana Hoi Yun , Kote‐Jarai, Zsofia , Muir, Kenneth , Giles, Graham G. , Wiklund, Fredrik E. , Khaw, Kay‐Tee , Cybulski, Cezary , Cannon‐Albright, Lisa , Teixeira, Manuel R , Eeles, Rosalind A , Schleutker, Johanna , Travis, Ruth C , Pashayan, Nora , Maclnnis, Robert , Haycock, Philip , Brenner, Hermann , Martin, Richard M , Batra, Jyotsna , Davey Smith, George

Mayo Clinic

Cancer Medicine | March 19, 2016 | Volume: 5 | Issue: 6 | Pages: 1125-1136

10.1002/cam4.695 | PMID 26992435 Get It

AbstractGenetic risk scores were used as unconfounded instruments for specific lipid traits (Mendelian randomization) to assess whether circulating lipids causally influence prostate cancer risk. Data from 22,249 prostate cancer cases and 22,133 controls from 22 studies within the international PRACTICAL consortium were analyzed. Allele scores based on single nucleotide polymorphisms (SNPs) previously reported to be uniquely associated with each of low‐density lipoprotein (LDL), high‐density lipoprotein (HDL), and triglyceride (TG) levels, were first validated in an independent dataset, and then entered into logistic regression models to estimate the presence (and direction) of any causal effect of each lipid trait on prostate cancer risk. There was weak evidence for an association between the LDL genetic score and cancer grade: the odds ratio (OR) per genetically instrumented standard deviation (SD) in LDL, comparing high‐ (≥7 Gleason score) versus low‐grade (<7 Gleason score) cancers was 1.50 (95% CI: 0.92, 2.46; P = 0.11). A genetically instrumented SD increase in TGs was weakly associated with stage: the OR for advanced versus localized cancer per unit increase in genetic risk score was 1.68 (95% CI: 0.95, 3.00; P = 0.08). The rs12916‐T variant in 3‐hydroxy‐3‐methylglutaryl‐CoA reductase (HMGCR) was inversely associated with prostate cancer (OR: 0.97; 95% CI: 0.94, 1.00; P = 0.03). In conclusion, circulating lipids, instrumented by our genetic risk scores, did not appear to alter prostate cancer risk. We found weak evidence that higher LDL and TG levels increase aggressive prostate cancer risk, and that a variant in HMGCR (that mimics the LDL lowering effect of statin drugs) reduces risk. However, inferences are limited by sample size and evidence of pleiotropy.
Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation
Fenske, Timothy S. , Ahn, Kwang Woo , Graff, Tara M., Digilio, Alessandro, Kamble, Rammurti T., Ayala, Ernesto , Brammer, Jonathan E. , Cairo, Mitchell S. , Chen, Andy , Chen, Yi‐Bin, D’Souza, Anita , Farooq, Umar , Freytes, Cesar, Ganguly, Siddhartha , Inwards, David J. , Kharfan‐Dabaja, Mohamed A. , Nathan, Sunita , Pawarode, Attaphol , Reddy, Nishitha , Seo, Sachiko , Sureda, Anna , Smith, Sonali M. , Inwards, David, Bashir, Qaiser , Bacher, Ulrike , Chen, Yi‐Bin , Chhabra, Saurabh , Farooq, Umar , Hertzberg, Mark , Jaglowski, Samantha , Lazarus, Hillard M. , Perales, Miguel‐Angel , Hamadani, Mehdi , Chen, Andy I. , D'Souza, Anita

Mayo Clinic

British Journal of Haematology | March 18, 2016 | Volume: 174 | Issue: 2 | Pages: 235-248

10.1111/bjh.14046 | PMID 26989808 Get It

Summary For diffuse large B‐cell lymphoma ( DLBCL ) patients progressing after autologous haematopoietic cell transplantation (auto HCT ), allogeneic HCT (allo HCT ) is often considered, although limited information is available to guide patient selection. Using the Center for International Blood and Marrow Transplant Research ( CIBMTR ) database, we identified 503 patients who underwent allo HCT after disease progression/relapse following a prior auto HCT . The 3‐year probabilities of non‐relapse mortality, progression/relapse, progression‐free survival ( PFS ) and overall survival ( OS ) were 30, 38, 31 and 37% respectively. Factors associated with inferior PFS on multivariate analysis included Karnofsky performance status ( KPS ) <80, chemoresistance, auto HCT to allo HCT interval <1‐year and myeloablative conditioning. Factors associated with worse OS on multivariate analysis included KPS <80, chemoresistance and myeloablative conditioning. Three adverse prognostic factors were used to construct a prognostic model for PFS , including KPS <80 (4 points), auto HCT to allo HCT interval <1‐year (2 points) and chemoresistant disease at allo HCT (5 points). This CIBMTR prognostic model classified patients into four groups: low‐risk (0 points), intermediate‐risk (2‐5 points), high‐risk (6‐9 points) or very high‐risk (11 points), predicting 3‐year PFS of 40, 32, 11 and 6%, respectively, with 3‐year OS probabilities of 43, 39, 19 and 11% respectively. In conclusion, the CIBMTR prognostic model identifies a subgroup of DLBCL patients experiencing long‐term survival with allo HCT after a failed prior auto HCT .